Clinical Trials Browser

Pancreatic Neoplasms

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Pancreatic Neoplasms

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Neoplasm Metastasis, Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Lymphoma, Large B-Cell, Diffuse

Neoplasms, Pancreatic Neoplasms

Pancreatic Neoplasms

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Pancreatic Neoplasms

Camurati-Engelmann Syndrome

Osteosarcoma

Biliary Tract Neoplasms

Urinary Bladder Neoplasms

Pancreatic Neoplasms

Neoplasms, Pancreatic Neoplasms

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

Pancreatic Neoplasms

Clinical Trials

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

A Study of ASP3082 in Adults With Advanced Solid Tumors

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

MUIR

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

A Study of LY3200882 in Participants With Solid Tumors

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

TASUC-Neo

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ARC-8

MTAPESTRY 103

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

ResQ108B-PANC